-
![Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide](/abs-image/US/2013/03/05/US08389727B2/abs.jpg.150x150.jpg)
1.发明授权Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide 有权固体形式的N-（4-（7-氮杂双环[2.2.1]庚烷-7-基）-2-三氟甲基）苯基）-4-氧代-5-（三氟甲基）-1,4-二氢喹啉-3-甲酰胺公开(公告)号：US08389727B2
公开(公告)日：2013-03-05
申请号：US12909789
申请日：2010-10-21
申请人： Beili Zhang , Mariusz Krawiec , Brian Luisi , Ales Medek
发明人： Beili Zhang , Mariusz Krawiec , Brian Luisi , Ales Medek
IPC分类号： C07D215/38
CPC分类号： A61K31/4748 , A61K31/4709 , C07B2200/13 , C07D487/08
摘要： The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith.
摘要翻译： 本发明涉及N-（4-（7-氮杂双环[2.2.1]庚-7-基）-2-（三氟甲基）苯基）-4-氧代-5-（三氟甲基） -1,4-二氢喹啉-3-甲酰胺（A-HCl型，B型，B-HCl型，或这些形式的任何组合），其药物组合物及其处理方法。
-
![Solid Forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide](/abs-image/US/2011/05/26/US20110123449A1/abs.jpg.150x150.jpg)
2.发明申请Solid Forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide 有权固体形式的N-（4-（7-氮杂双环[2.2.1]庚烷-7-基）-2-三氟甲基）苯基）-4-氧代-5-（三氟甲基）-1,4-二氢喹啉-3-甲酰胺公开(公告)号：US20110123449A1
公开(公告)日：2011-05-26
申请号：US12909789
申请日：2010-10-21
申请人： Beili Zhang , Mariusz Krawiec , Brian Luisi , Ales Medek
发明人： Beili Zhang , Mariusz Krawiec , Brian Luisi , Ales Medek
IPC分类号： A61K49/00 , C07D401/14 , A61K31/4709 , A61P11/00 , A61P1/00 , A61P3/00 , A61P19/02 , A61P25/00 , C12Q1/02
CPC分类号： A61K31/4748 , A61K31/4709 , C07B2200/13 , C07D487/08
摘要： The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith.
摘要翻译： 本发明涉及N-（4-（7-氮杂双环[2.2.1]庚-7-基）-2-（三氟甲基）苯基）-4-氧代-5-（三氟甲基） -1,4-二氢喹啉-3-甲酰胺（A-HCl型，B型，B-HCl型，或这些形式的任何组合），其药物组合物及其处理方法。
-
![SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA](/abs-image/US/2012/07/19/US20120184741A1/abs.jpg.150x150.jpg)
3.发明申请SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA 有权γ-乙基-3- [5- [2-（1-羟基 - 甲基）乙基]嘧啶-5-基] -7-（四氢呋喃-2-基）-1H-苯并咪唑的固体形式 -2-YL]尿素公开(公告)号：US20120184741A1
公开(公告)日：2012-07-19
申请号：US13349845
申请日：2012-01-13
申请人： Dean Shannon , Brian Luisi , Yusheng Liao , Mariusz Krawiec
发明人： Dean Shannon , Brian Luisi , Yusheng Liao , Mariusz Krawiec
IPC分类号： C07D405/14
CPC分类号： C07D405/14 , C07D407/04
摘要： The present application is directed to solid forms of compounds of formula (I): and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infection.
摘要翻译： 本申请涉及抑制细菌促旋酶和/或Topo IV的式（I）化合物及其药学上可接受的盐的固体形式，以及包含所述化合物和盐的药物组合物。 这些化合物和盐可用于治疗细菌感染。
-
![Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea](/abs-image/US/2013/07/09/US08481552B2/abs.jpg.150x150.jpg)
4.发明授权Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-YL]urea 有权回旋酶抑制剂（R）-1-乙基-3- [5- [2-（1-羟基-1-甲基 - 乙基）嘧啶-5-基] -7-（四氢呋喃-2-基）-1H - 苯并咪唑-2-基]脲公开(公告)号：US08481552B2
公开(公告)日：2013-07-09
申请号：US13349845
申请日：2012-01-13
申请人： Dean Shannon , Brian Luisi , Yusheng Liao , Mariusz Krawiec
发明人： Dean Shannon , Brian Luisi , Yusheng Liao , Mariusz Krawiec
IPC分类号： A01N43/54 , C07D239/42 , C07D471/04
CPC分类号： C07D405/14 , C07D407/04
摘要： The present application is directed to solid forms of compounds of formula (I): and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infection.
摘要翻译： 本申请涉及抑制细菌促旋酶和/或Topo IV的式（I）化合物及其药学上可接受的盐的固体形式，以及包含所述化合物和盐的药物组合物。 这些化合物和盐可用于治疗细菌感染。
-
![Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea](/abs-image/US/2013/07/02/US08476281B2/abs.jpg.150x150.jpg)
5.发明授权Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea 有权回旋酶抑制剂（R）-1-乙基-3- [6-氟-5- [2-（1-羟基-1-甲基 - 乙基）嘧啶-5-基] -7-（四氢呋喃-2-基） 吡啶-2-基] -1H-苯并咪唑-2-基]脲公开(公告)号：US08476281B2
公开(公告)日：2013-07-02
申请号：US13349984
申请日：2012-01-13
IPC分类号： A01N43/54 , C07D239/42 , C07D471/04
CPC分类号： C07D405/14 , A61K31/4184 , A61K31/506
摘要： The present application is directed to solid forms of compounds of formula I: and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.
摘要翻译： 本申请涉及固体形式的式I化合物及其药学上可接受的盐，其抑制细菌促旋酶和/或Topo IV以及包含所述化合物和盐的药物组合物。 这些化合物和盐可用于治疗细菌感染。
-
![SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA](/abs-image/US/2012/07/19/US20120184564A1/abs.jpg.150x150.jpg)
6.发明申请SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA 有权γ-烯丙基-3- [6-氟-5- [2-（1-羟基-1-甲基 - 乙基）嘧啶-5-基] -7-（四氢呋喃-2-基） YL）-1H-BENZIMIDAZOL-2-YL] UREA公开(公告)号：US20120184564A1
公开(公告)日：2012-07-19
申请号：US13349984
申请日：2012-01-13
IPC分类号： A61K31/506 , A61P31/04 , C07D405/14
CPC分类号： C07D405/14 , A61K31/4184 , A61K31/506
摘要： The present application is directed to solid forms of compounds of formula I: and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.
摘要翻译： 本申请涉及固体形式的式I化合物及其药学上可接受的盐，其抑制细菌促旋酶和/或Topo IV以及包含所述化合物和盐的药物组合物。 这些化合物和盐可用于治疗细菌感染。
-
![Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide](/abs-image/US/2013/10/24/US20130281487A1/abs.jpg.150x150.jpg)
7.发明申请Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 有权固体形式的N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺公开(公告)号：US20130281487A1
公开(公告)日：2013-10-24
申请号：US13452758
申请日：2012-04-20
申请人： Brian Luisi , Sneha Ghanshyam Arekar , Adriana Costache , Kirk Raymond Dinehart , Steven C. Johnston , Bobbianna J. Neubert-Lagille
发明人： Brian Luisi , Sneha Ghanshyam Arekar , Adriana Costache , Kirk Raymond Dinehart , Steven C. Johnston , Bobbianna J. Neubert-Lagille
IPC分类号： C07D215/56 , A61P11/08 , A61P31/04 , A61P31/00 , A61P29/00 , A61P11/00 , A61P37/00 , A61P11/06 , A61P11/02 , A61P1/10 , A61P1/18 , A61P15/08 , A61P37/08 , A61P1/16 , A61P7/04 , A61P25/28 , A61P25/16 , A61P19/10 , A61P19/08 , A61P3/10 , A61P27/04 , A61K31/47
CPC分类号： C07D215/56 , A61K31/47 , A61K45/06 , A61K2300/00
摘要： The present invention relates to crystalline solvate forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith.
摘要翻译： 本发明涉及N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1）的结晶溶剂合物形式， 他们的准备。 本发明还涉及包含结晶溶剂化物形式的药物组合物，以及其处理方法。
-
![Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide](/abs-image/US/2014/03/18/US08674108B2/abs.jpg.150x150.jpg)
8.发明授权Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 有权固体形式的N- [2,4-二（1,1-二甲基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺公开(公告)号：US08674108B2
公开(公告)日：2014-03-18
申请号：US13452758
申请日：2012-04-20
申请人： Brian Luisi , Sneha Ghanshyam Arekar , Adriana Costache , Kirk Raymond Dinehart , Steven C. Johnston , Bobbianna J. Neubert-Langille
发明人： Brian Luisi , Sneha Ghanshyam Arekar , Adriana Costache , Kirk Raymond Dinehart , Steven C. Johnston , Bobbianna J. Neubert-Langille
IPC分类号： C07D215/38
CPC分类号： C07D215/56 , A61K31/47 , A61K45/06 , A61K2300/00
摘要： The present invention relates to crystalline solvate forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith.
摘要翻译： 本发明涉及N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1）的结晶溶剂合物形式， 他们的准备。 本发明还涉及包含结晶溶剂化物形式的药物组合物，以及其处理方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.033 秒)
